What is Alector, Inc.'s market cap?

Alector, Inc. (ALEC) has a market capitalization of $214.9M and trades on NASDAQ.

Who are Alector, Inc.'s competitors?

Alector, Inc.'s key competitors include Denali Therapeutics, Biogen, Eli Lilly, and others. These companies compete in similar markets and product categories.

Who does Alector, Inc. partner with?

Alector, Inc.'s notable partners include GlaxoSmithKline, Adimab.

Where is Alector, Inc. headquartered?

Alector, Inc. is headquartered in United States of America and employs approximately 244 people. It has been publicly traded since 2019.

Alector, Inc. (ALEC) Stock Fundamentals & Financials

Alector is a clinical-stage biotechnology company focused on developing immuno-neurology therapies for neurodegenerative diseases.

Market cap

$214.94M-28.0%

Earnings

Q2 2026 report

August 6, 2026

Revenue$3.3MBeat by $1.6M EPS-$0.21Beat by $0.02

Read the full report

Next report

Nov 5, 2026 (in 2 months)

Revenue estimate$2.9M

EPS estimate-$0.24

Competitors

By market cap

Eli Lilly$1.01T+48.8%

Merck & Co.$357.52B+76.4%

Biogen$31.9B+50.3%

Denali Therapeutics Inc.$3.2B+67.9%

Alector, Inc.$214.9M-28.0%

ProMIS Neurosciences$115.5M+390%

NXT

NextCure, Inc.$27.6M+85.8%

Aptevo Therapeutics$3.1M-99.1%

By revenue growth

Denali Therapeutics Inc.+184%

Eli Lilly+49.6%

Merck & Co.+4.6%

Biogen+0.3%

By net margin

Eli Lilly33.53%+7.6pp

Biogen8.81%-6.5pp

Merck & Co.4.77%-21.0pp

Denali Therapeutics Inc.-33,121.86%+23,617pp

Profile

Alector is a clinical-stage biotechnology company focused on developing immuno-neurology therapies for neurodegenerative diseases. The company leverages human genetics and its proprietary Alector Brain Carrier (ABC) platform to engineer antibodies, enzymes, and siRNA that cross the blood-brain barrier to restore healthy immune function in the brain.

Competitive position

Alector is a pioneer in the immuno-neurology space, utilizing a proprietary blood-brain barrier delivery platform to differentiate its pipeline from traditional CNS therapies.

GeographiesUnited States, Global

Customer segmentsBiopharmaceutical companies, Patients

Business modelR&D, Licensing, Collaboration

SuppliersContract Development and Manufacturing Organizations (CDMOs), Academic research institutions, Clinical trial site operators

CustomersLarge pharmaceutical companies, Specialty biotechnology firms, Healthcare providers

CountryUnited States of America

Listed2019

Employees244.0

CEOArnon Rosenthal

SectorHealthcare

IndustryBiotechnology

Websitealector.com

FilingsSEC EDGAR

FAQ

What is Alector, Inc.'s market cap?: Alector, Inc. (ALEC) has a market capitalization of $214.9M and trades on NASDAQ.
Who are Alector, Inc.'s competitors?: Alector, Inc.'s key competitors include Denali Therapeutics, Biogen, Eli Lilly, and others. These companies compete in similar markets and product categories.
Who does Alector, Inc. partner with?: Alector, Inc.'s notable partners include GlaxoSmithKline, Adimab.
Where is Alector, Inc. headquartered?: Alector, Inc. is headquartered in United States of America and employs approximately 244 people. It has been publicly traded since 2019.